Gatipotuzumab

Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.[1] Gatipotuzumab is being developed by Glycotope GMBH [2] and is undergoing a phase II clinical trial for ovarian cancer.[3]

Gatipotuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targettumor specific glycosylation of MUC1
Clinical data
Other namesPankoMab-GEX, anti-TA-MUC1
ATC code
  • None
Identifiers
CAS Number
ChemSpider
  • none
UNII

References

  1. "Gatipotuzumab". Drug Dictionary. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
  2. "Gatipotuzumab – Our first-in-class GlycoBody against the novel tumor-specific TA-MUC1 epitope". Glycotope GmbH.
  3. Clinical trial number NCT01899599 for "PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer " at ClinicalTrials.gov
  • "Gatipotuzumab". Drug Information Portal. U.S. National Library of Medicine.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.